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Macrophages and nitric oxide: A deadly combination
In the late 1980s, Carl Nathan and colleagues pinpointed nitric oxide (NO) 
as a molecule that macrophages use to kill tumor cells. This discovery helped 
verify the role of radicals as signaling molecules in the immune system.
Immunologists in the early 1980s thought 
immune signaling occurred mainly 
through macromolecules that bind to 
specific cell receptors. They would 
soon be stunned to find that nitric 
oxide (NO)—a small, chemically reac-
tive gas, not even known to be made 
by eukaryotes—is used by immune 
cells to kill tumor cells.
Mixed signals?
The immunology field got a hint that 
NO might be a host product in 1985, 
when Michael Marletta and his graduate 
student Dennis Stuehr at the Massachu-
setts Institute of Technology found an 
ex  cess of nitrate in the urine of bac-
terially infected mice (1). To find its 
source, the researchers focused on mac-
rophages, immune cells that help defend 
against infections.
Meanwhile, at the University of 
Utah, John Hibbs Jr. was also studying 
macrophages. He wanted to identify 
the ingredients in a cell culture medium 
that macrophages needed to kill tumor 
cells. The key ingredient was the amino 
acid arginine. When arginine was 
present, the activated macrophages 
removed its guanidino group, producing 
nitrite. An arginine analogue that could 
not be catabolized prevented tumor cell 
killing (2). But exposing tumor cells to 
nitrite alone did not kill them. Hibbs 
concluded that macrophages must be 
converting arginine into a reactive 
nitrogen intermediate (RNI), which then 
decomposed into nontoxic nitrite.
Getting the message
A contemporary of Hibbs, Carl Nathan at 
Cornell University Medical College, saw 
similarities between Hibbs’s research and 
his own. A decade earlier, Nathan had 
discovered that activated macrophages 
release hydrogen peroxide and other 
reactive oxygen intermediates (ROI) (3). 
He and his colleagues found that ROI 
contributed to macrophages’ abilities to 
kill tumor cells and pathogens in vitro and 
in vivo. This conclusion, however, was 
not accepted by some scientists, who had 
a hard time imagining how a cell could 
keep a rein on these seemingly indiscrimi-
nate toxic molecules. But when Nathan 
heard about RNI, he recognized poten-
tial parallels with ROI. It struck him that 
evolution had selected at least two differ-
ent sets of small, inorganic reactive chemi-
cal species for cytotoxic roles. He invited 
Stuehr to join his lab as a postdoc. They 
set out to see what sort of RNI was made 
by activated macrophages, whether and 
how this product killed tumor cells, and 
what enzyme produced it.
NO kills
The same year that Stuehr joined 
Nathan’s lab, a team headed by physi-
ologist Salvador Moncada of University 
College London, UK, published a pa-
per demonstrating that endothelium-
derived relaxing factor, which causes 
blood vessel dilation, was indistinguish-
able from the radical gas NO (4).
Nathan and Stuehr then performed 
cell culture studies showing that acti-
vated macrophages also make endothe-
lium-derived relaxing factor, a.k.a., 
NO (5). They later showed that NO 
killed tumor cells by inhibiting mito-
chondrial electron transport (6). Both 
studies were published in 1989 in the 
Journal of Experimental Medicine.
“The work brought together in one 
clear study the importance of NO in the 
immune surveillance system,” says fel-
low NO researcher David Wink from 
the National Cancer Institute. “Two 
decades after its publication, we are still 
finding new and remarkable opportuni-
ties for therapy and cancer prevention 
through the conversation about NO and 
cancer that these papers started.”
The findings also reconciled the 
idea that NO could be used for both a 
physiological response—such as blood 
vessel dilation—and a defensive re-
sponse. “It’s a matter of degree,” says 
Nathan. At high levels, NO kills cells. 
But at low levels, it is able to regulate 
physiological responses, such as mito-
chondrial respiration (7).
Nathan’s lab has since purified and 
cloned the enzyme that makes NO in 
activated macrophages, which they 
called iNOS (8, 9). With John Mudgett 
and colleagues at Merck, they created 
an iNOS knockout mouse (10). These 
mutant mice were sent to over 130 
laboratories, where they were used to 
identify many more functions for iNOS-
derived NO, including diverse signaling 
pathways and the killing of viruses, bac-
teria, and protozoa (11).
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